Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2024-03-25 Declaration of Voting R…
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Results of Meeting 2 pages 198.6KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a public announcement dated 26 March 2024 regarding the results of an Extraordinary General Meeting (EGM) of Algorae Pharmaceuticals Limited. It includes detailed proxy vote counts and poll results for resolutions voted on at the meeting. The content focuses on the official disclosure of voting outcomes, consistent with regulatory requirements under the Corporations Act 2001 and ASX Listing Rules. There is no indication that this is a full report or financial statement; rather, it is a formal announcement of voting results from a shareholder meeting. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused solely on voting results, reinforcing this classification.
2024-03-25 English
Upcoming Expiry Of 1AIOA Quoted Option Series 2 pages 226.0KB
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Algorae Pharmaceuticals Limited regarding the upcoming expiry of a quoted option series (ASX code 1AIOA). It provides detailed information about the number of options expiring, exercise price, expiry date, market prices, and other relevant details for option holders. The document is an official notification to security holders and the market about the expiry of options and does not contain financial statements, management discussion, or detailed financial results. It is not a report or a presentation but an announcement related to capital instruments (options) and their expiry. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as option expiries.
2024-03-19 English
Artificial Intelligence Platform Update 3 pages 448.6KB
Regulatory Filings Classification · 95% confidence The document is a public announcement from Algorae Pharmaceuticals Limited providing a development update on their AlgoraeOS Artificial Intelligence Biopharmaceutical Prediction Platform for Drug Discovery. It contains detailed information about the progress, technology, collaborations, and future plans related to the AI platform. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The document is not a transcript, audit report, or legal proceeding update. It is a corporate update focused on development progress and strategic initiatives, which fits best under a general regulatory announcement category. The document length is 9730 characters, which is substantial but the content is clearly an announcement rather than a full report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other specific categories.
2024-03-07 English
Application for quotation of securities - 1AI 6 pages 18.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) form used for the application for quotation of securities. It details the issuance and quotation of securities resulting from options being exercised or convertible securities being converted. The document includes specifics about the securities, issue dates, and the total number of securities to be quoted. This type of document is not a financial report, earnings release, or management discussion, but rather an official announcement related to capital changes and securities quotation on the exchange. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2024-03-07 English
Cleansing Notice 1 page 232.2KB
Capital/Financing Update Classification · 95% confidence The document is a public announcement titled 'Section 708A (5)(e) Cleansing Notice' issued by Algorae Pharmaceuticals Limited. It references the issuance of fully paid ordinary shares upon conversion of listed options and compliance with specific sections of the Corporations Act 2001 (Cth). The content focuses on confirming the issuance of shares without disclosure under certain legal provisions and compliance with regulatory requirements. This type of notice is related to capital structure changes and fundraising activities, specifically the issuance of shares and related regulatory compliance. The document is short (1405 characters) and is a formal announcement of a capital/financing event rather than a detailed financial report or other filing types. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-03-07 English
Half Yearly Report Announcement and Appendix 4D 4 pages 1.1MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half Yearly Report Ended 31 December 2023' and includes financial data for the six months ended 31 December 2023, such as revenue, profit/loss, net tangible assets, and dividend information. It references a 'Consolidated Interim Financial Report' and states that the half-yearly report is to be read with the most recent annual report. The document also includes an Appendix 4D, which is a regulatory filing used in Australia for half-year financial reporting. The length of the document (7982 characters) and the inclusion of substantive financial data and analysis confirm it is a comprehensive interim report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-02-28 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.